Navigation Links
Curemark LLC Reports Positive Phase III Results of CM-AT in Children With Autism
Date:12/7/2011

RYE, N.Y., Dec. 7, 2011 /PRNewswire/ -- Curemark LLC, a Rye, New York-based drug research and development company, today announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints.  The trial compared CM-AT to placebo in children with autism aged 3 – 8.  Top line results demonstrate a statistically significant effect of CM-AT over placebo on both core and non-core symptoms of autism.  Analysis of the full trial data is ongoing and the results will be presented at an upcoming medical meeting.

"We are extremely pleased with the results of our trial," said Dr. Joan Fallon, CEO of Curemark. "We wish to thank all the children and their parents who participated in the study, and look forward to a full review of the data by the FDA."

CM-AT has been granted Fast Track status by the Food and Drug Administration (FDA). The fast track programs of the Food and Drug Administration are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

About Curemark LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD.  In addition to CM-AT for autism, Curemark has two more drugs in development.  These are CM-4612 for Attention Deficit Hyperactivity Disorder (ADHD), for which the company has open Investigational New Drug (IND) clearance to conduct Phase III trials, and
'/>"/>

SOURCE Curemark LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Curemark Issued Patent for the Diagnosis of Parkinsons Disease
2. Curemark Reports Positive Results for Novel Compound CM-182 in Amphetamine Induced Hyperactivity
3. Curemark Completes Enrollment of Phase III Autism Trials
4. Curemark Hosts New York Senator Kirsten Gillibrand
5. Curemark Appoints Jennifer Katritos, CPA as Vice President of Finance
6. Curemark Announces Four New Sites Participating in Autism Study
7. Curemark Awarded Qualifying Therapeutic Discovery Project (QTDP) Grant
8. Curemark Moderates Autism Panel at Life Sciences Summit 2010
9. Curemark Presents at the Rodman & Renshaw Annual Global Investment Conference
10. James F. Szigethy Named Curemarks Director of New Product Development
11. Curemark to Present at BioPharm America™ 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 3, 2015  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: ... on its expertise in opioid antagonists, announced today ... treating opioid overdose with intranasal naloxone, has commenced ... (NDA) to the United States Food and Drug ... naloxone, a drug intended to treat opioid overdose. ...
(Date:6/3/2015)...  The International Confederation of Midwives (ICM) has provided ... a standard for midwives trained to ICM,s competency standards.  ... consultation with ICM experts. Direct Relief will provide the ... As many as one in 30 women ... childbirth.  Skilled birth attendants such as midwives offer the ...
(Date:6/3/2015)... 2015 According to a ... Vascular Devices Market (Embolic Protection, Chronic Total Occlusion, ... IVC Filters, Stents, Balloons and Accessories) - Forecasts ... and Peripheral Vascular Devices Market is expected to ... CAGR of 7.4% from 2014 to 2019. ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 2A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 3A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 4The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4
... Dec. 29, 2011 BioDelivery Sciences International, Inc. (Nasdaq: ... announcement by the U.S. Food and Drug Administration (FDA) ... transmucosal fentanyl products has been approved.  The program, which ... Fentanyl (TIRF) REMS Access Program, was designed to ensure ...
... ESRX ) announced that it will present at ... 2012 at 9:00 a.m. PST (12:00 p.m. EST) at the ... The presentation will also be broadcast via the Internet and ... Scripts web site at http://www.express-scripts.co m .  RealPlayer ...
Cached Medicine Technology:ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 2ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 3ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 4
(Date:6/3/2015)... (PRWEB) June 03, 2015 A ... additional precautions on product labels underscores the importance ... according to the American Society for Dermatologic Surgery ... include new warnings about the risks for serious ... vessels. While product labels already include information about ...
(Date:6/3/2015)... Loma Linda University Health and Adventist ... Gorgonio Memorial Hospital (SGMH). The SGMH board voted unanimously ... , “Loma Linda University Health has been serving the ... executive officer, Loma Linda University Medical Center. “We are ... to this community.” , Under the proposed affiliation, ...
(Date:6/3/2015)... June 03, 2015 Johnson & Johnson ... $7.8 million to resolve a Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ... the company allegedly used to market the antipsychotic drug. ... indicate that the Arkansas Attorney General moved to dismiss ... accord. The Risperdal settlement amounts to just a fraction ...
(Date:6/3/2015)... DC (PRWEB) June 03, 2015 The ... to announce that Maria C. Savoia, M.D., Dean of Medical ... of Medicine, will become Chair on July 1. ... Chair of the National Resident Matching Program,” said Dr. Savoia. ... reliable process for matching medical students with training programs, and ...
(Date:6/3/2015)... On the heels of a report predicting ... 2020 ( click here to review news coverage about ... Baltimore has the talent to become a world-leading center ... and other biological data are collected and analyzed to help ... all the elements of a perfect storm for bioinformatics leadership,” ...
Breaking Medicine News(10 mins):Health News:ASDSA Supports FDA Fillers Directive 2Health News:ASDSA Supports FDA Fillers Directive 3Health News:ASDSA Supports FDA Fillers Directive 4Health News:Loma Linda University Health and Adventist Health Enter into Exclusive Affiliation Negotiations with San Gorgonio Memorial Hospital 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 2Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 3Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 4Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3
... stage III colon cancer treated with 5-FU-based chemotherapy after ... improved overall survival with no change in time to ... patients with stage II colon cancer treated after 1995 ... to death compared to those patients treated prior to ...
... ... Days of Intentions to mark the mid-point of 2010. , ... Los Angeles, CA (PRWEB) June 3, 2010 -- This week, Intent.com launches ... Days of Intentions is a challenge to the internet community to commit to posting one new ...
... Davis public health researchers have found that children, who ... choices, are the targets of a new medium used ... an entertaining blend of interactive animation, video content and ... online messages that primarily promote corporate branding and products. ...
... high school, study finds , THURSDAY, June 3 (HealthDay News) ... the two years following high school are less likely to ... , The finding builds on past research that had demonstrated ... and alcohol abuse. , "I,m not saying that we should ...
... but others say it,s not always that simple, , THURSDAY, ... prompts anxiety in many a parent. But having to ... story can make an already sensitive subject even more complicated. ... parents. , As assisted reproduction technology, in which someone other ...
... ... ... 2010 -- Thomas D. Meade, M.D., a nationally renowned knee specialist who has performed ... June 1, Dr. Meade will see patients at Coordinated Health facilities in Allentown, Bethlehem, ...
Cached Medicine News:Health News:Stage II and stage III colon cancer patients treated after 1995 have improved overall survival 2Health News:Intent.com Launches 30 Days of Intentions and Announces Winners of 2010 Intent Web Awards 2Health News:Online games new marketing tool for unhealthy foods 2Health News:Online games new marketing tool for unhealthy foods 3Health News:Romance May Steer Young Adults Away From Booze, Pot 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 3Health News:Nationally Renowned Knee Specialist Dr. Thomas Meade Joins Coordinated Health 2Health News:Nationally Renowned Knee Specialist Dr. Thomas Meade Joins Coordinated Health 3
The PowerLab/4ST is a high-performance recording unit with built-in amplifiers and is suitable for physiology teaching. It has been designed to cover the broad experimental requirements in life scien...
... data acquisition system suitable for a wide ... animal physiology, pharmacology, neurophysiology, biology, zoology, biochemistry, ... of recording from very slow to very ... per second continuously to disk), and is ...
Worth 4-Dot Flashlight/Plastic for testing and training of visual functions and testing for fusion, suppression and/or diplopia. Red/green goggle included. Requires 2 C batteries (not included)....
They employ Lea Symbols. Contrast levels are the same at 25%, 10%, 5%, 2.5% and 1.25%. Each offers a different set of Lea Symbols to guard against memorization. Also uses recording forms (P/N 215400)...
Medicine Products: